Scholarlink

Background <p>In recent years, neoadjuvant therapy (NAT) has received growing interest and is now the standard of care for borderline resectable (BR) pancreatic cancer (PC) and locally advanced (LA) PC. Despite the proven benefits of both NAT and adjuvant therapy (AT), a critical question remains: whether patients undergoing pancreatectomy after NAT still benefit from additional adjuvant chemotherapy. In this systematic review and meta-analysis, we aimed to answer that question and explore potential subgroups and regimens that increase or decrease a potential survival advantage.</p> Methods <p>A comprehensive systematic literature search was performed. The primary outcome measure was overall survival (OS), expressed as hazard ratios (HRs). HRs and their corresponding 95% confidence intervals (CIs) were collected to compare survival between patients who did and did not receive AT. The ROBINS-I-tool was used to assess the risk of bias for all included non-randomized studies.</p> Results <p>Overall, 29,119 patients from 30 articles with PC who underwent NAT and surgical resection with reporting of AT were included. Patients who received AT after NAT and surgical resection demonstrated a significantly longer OS, with a pooled HR of 0.85 (95% CI 0.8–0.89; p&lt;0.0001). Patients with N0 disease gained benefit from AT, with an HR of 0.87 (95% CI 0.80–0.94; p=0.0008). AT after NAT in patients with N+ disease demonstrated an even clearer improved OS, with an HR of 0.74 (95% CI 0.65–0.85; p&lt;0.0001).</p> Conclusion <p>AT after NAT and surgical resection may improve OS, especially for patients with a positive nodal status, but, importantly, also for patients with a negative nodal status. Future studies should focus on detailed reporting of chemotherapy regimens and resectability criteria.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Benefit of Adjuvant Therapy After Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis

  • 期刊论文

  • 发表日期：

    2026年6月3日

查看全文
  • Michael C. Frey,
  • Victor Lopez-Lopez,
  • Alessia Benz,
  • Sarvar Abdurakhmonov,
  • Haleh Amirian,
  • Jashodeep Datta,
  • So Heun Lee,
  • Changhoon Yoo,
  • Ning Pu,
  • Chunmeng Zhang,
  • Bradley N. Reames,
  • Ralph Fritsch,
  • Henrik Petrowsky,
  • José Oberholzer,
  • Dilmurodjon Eshmuminov

摘要

Background

In recent years, neoadjuvant therapy (NAT) has received growing interest and is now the standard of care for borderline resectable (BR) pancreatic cancer (PC) and locally advanced (LA) PC. Despite the proven benefits of both NAT and adjuvant therapy (AT), a critical question remains: whether patients undergoing pancreatectomy after NAT still benefit from additional adjuvant chemotherapy. In this systematic review and meta-analysis, we aimed to answer that question and explore potential subgroups and regimens that increase or decrease a potential survival advantage.

Methods

A comprehensive systematic literature search was performed. The primary outcome measure was overall survival (OS), expressed as hazard ratios (HRs). HRs and their corresponding 95% confidence intervals (CIs) were collected to compare survival between patients who did and did not receive AT. The ROBINS-I-tool was used to assess the risk of bias for all included non-randomized studies.

Results

Overall, 29,119 patients from 30 articles with PC who underwent NAT and surgical resection with reporting of AT were included. Patients who received AT after NAT and surgical resection demonstrated a significantly longer OS, with a pooled HR of 0.85 (95% CI 0.8–0.89; p<0.0001). Patients with N0 disease gained benefit from AT, with an HR of 0.87 (95% CI 0.80–0.94; p=0.0008). AT after NAT in patients with N+ disease demonstrated an even clearer improved OS, with an HR of 0.74 (95% CI 0.65–0.85; p<0.0001).

Conclusion

AT after NAT and surgical resection may improve OS, especially for patients with a positive nodal status, but, importantly, also for patients with a negative nodal status. Future studies should focus on detailed reporting of chemotherapy regimens and resectability criteria.